{"description":"Documents matching 'telemedicine' and from Drug Enforcement Administration","count":50,"total_pages":3,"next_page_url":"https://www.federalregister.gov/api/v1/documents?conditions%5Bagencies%5D%5B%5D=drug-enforcement-administration&conditions%5Bterm%5D=telemedicine&format=json&page=2","results":[{"title":"Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications","type":"Rule","abstract":"The Drug Enforcement Administration (DEA) jointly with the Department of Health and Human Services (HHS) is issuing a fourth extension of telemedicine flexibilities for the prescribing of controlled medications through December 31, 2026.","document_number":"2025-24123","html_url":"https://www.federalregister.gov/documents/2025/12/31/2025-24123/fourth-temporary-extension-of-covid-19-telemedicine-flexibilities-for-prescription-of-controlled","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-12-31/pdf/2025-24123.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-24123.pdf?1767102321","publication_date":"2025-12-31","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"},{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"}],"excerpts":"substances via <span class=\"match\">telemedicine</span>. The extension ensured and provided time for stakeholders to prepare for new rules.\n \n \n \n 8 \n  Third Temporary Extension of COVID-19 <span class=\"match\">Telemedicine</span> Flexibilities for Prescription of Controlled Medications, 89 FR 91253 (November 19, 2024).\n \n \n The Special Registration for <span class=\"match\">Telemedicine</span> NPRM \n \n On January 17, 2025, DEA published the “Special Registrations for <span class=\"match\">Telemedicine</span> and Limited State <span class=\"match\">Telemedicine</span> Registrations” Notice of Proposed Rulemaking (NPRM), which proposed a framework for a Special Registration for <span class=\"match\">Telemedicine</span>, pursuant"},{"title":"Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients","type":"Rule","abstract":"In the January 17, 2025, issue of the Federal Register, the Drug Enforcement Administration and the Department of Health and Human Services published two final rules related to the practice of telemedicine, titled \"Expansion of Buprenorphine Treatment via Telemedicine Encounter\" and \"Continuity of Care via Telemedicine for Veterans Affairs Patients.\" These final rules were originally scheduled to become final on February 18, 2025. In accordance with the Presidential Memorandum of January 20, 2025, titled \"Regulatory Freeze Pending Review,\" the Drug Enforcement Administration and the Department of Health and Human Services delayed the effective dates of these two final rules to March 21, 2025, by issuing a final rule; delay of effective dates and request for comments in the February 19, 2025, issue of the Federal Register. The Drug Enforcement Administration received 32 comments in response to the request for public comments regarding the delayed effective date. Considering these comments, the Department of Justice wishes to further postpone the effective dates for the purpose of further reviewing any questions of fact, law, and policy that the rules may raise. Therefore, the Drug Enforcement Administration and the Department of Health and Human Services will delay the effective date of the two final rules titled \"Expansion of Buprenorphine Treatment via Telemedicine Encounter\" and \"Continuity of Care via Telemedicine for Veterans Affairs Patients\" to December 31, 2025.","document_number":"2025-05007","html_url":"https://www.federalregister.gov/documents/2025/03/24/2025-05007/expansion-of-buprenorphine-treatment-via-telemedicine-encounter-and-continuity-of-care-via","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-03-24/pdf/2025-05007.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-05007.pdf?1742501707","publication_date":"2025-03-24","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"},{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"}],"excerpts":"“Expansion of Buprenorphine Treatment via <span class=\"match\">Telemedicine</span> Encounter” (90 FR 6504) and “Continuity of Care via <span class=\"match\">Telemedicine</span> for Veterans Affairs Patients” (90 FR 6523). These rules, respectively, amended their regulations to expand the circumstances under which: (1) practitioners registered by DEA are authorized to prescribe schedule III-V controlled substances approved by the Food and Drug Administration for the treatment of opioid use disorder via a <span class=\"match\">telemedicine</span> encounter, including an audio-only <span class=\"match\">telemedicine</span> encounter \n 1 \n \n and (2) Department of"},{"title":"Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients","type":"Rule","abstract":"In the January 17, 2025, issue of the Federal Register, the Drug Enforcement Administration and the Department of Health and Human Services published two final rules related to the practice of telemedicine, titled \"Expansion of Buprenorphine Treatment via Telemedicine Encounter\" and \"Continuity of Care via Telemedicine for Veterans Affairs Patients.\" These final rules were scheduled to become final on February 18, 2025. In accordance with the Presidential Memorandum of January 20, 2025, titled \"Regulatory Freeze Pending Review,\" the Drug Enforcement Administration and the Department of Health and Human Services are delaying the effective dates of these two final rules to March 21, 2025, and are soliciting public comments specifically regarding this delayed effective date.","document_number":"2025-02793","html_url":"https://www.federalregister.gov/documents/2025/02/19/2025-02793/expansion-of-buprenorphine-treatment-via-telemedicine-encounter-and-continuity-of-care-via","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-02-19/pdf/2025-02793.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-02793.pdf?1739540714","publication_date":"2025-02-19","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"},{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"}],"excerpts":"“Expansion of Buprenorphine Treatment via <span class=\"match\">Telemedicine</span> Encounter” (90 FR 6504) and “Continuity of Care via <span class=\"match\">Telemedicine</span> for Veterans Affairs Patients” (90 FR 6523). These rules, respectively, amended their regulations to expand the circumstances under which: (1) practitioners registered by DEA are authorized to prescribe schedule III-V controlled substances approved by the Food and Drug \n \n Administration for the treatment of opioid use disorder via a <span class=\"match\">telemedicine</span> encounter, including an audio-only <span class=\"match\">telemedicine</span> encounter \n 1 \n \n and (2) Department of"},{"title":"Special Registrations for Telemedicine and Limited State Telemedicine Registrations","type":"Proposed Rule","abstract":"The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 (the \"Ryan Haight Act\") generally requires an in-person medical evaluation prior to the issuance of a prescription of controlled substances but provides an exception to this in-person medical evaluation requirement where the practitioner is engaged in the \"practice of telemedicine\" within the meaning of the Ryan Haight Act. These proposed regulatory changes would establish a Special Registration framework and authorize three types of Special Registration. This proposed rulemaking also provides for heightened prescription, recordkeeping, and reporting requirements. DEA believes such changes are necessary to effectively expand patient access to controlled substance medications via telemedicine while mitigating the risks of diversion associated with such expansion. A summary of this rule may be found at https://www.regulations.gov/docket/DEA-2023-0029.","document_number":"2025-01099","html_url":"https://www.federalregister.gov/documents/2025/01/17/2025-01099/special-registrations-for-telemedicine-and-limited-state-telemedicine-registrations","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-01-17/pdf/2025-01099.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-01099.pdf?1736948758","publication_date":"2025-01-17","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"Registrations for <span class=\"match\">Telemedicine</span>: \n (1) a \n <span class=\"match\">Telemedicine</span> Prescribing Registration, \n authorizing qualified \n clinician practitioners \n to prescribe Schedule III-V controlled substances via <span class=\"match\">telemedicine</span>, (2) an \n Advanced <span class=\"match\">Telemedicine</span> Prescribing Registration, \n authorizing qualified, specialized \n clinician practitioners \n (\n e.g., \n psychiatrists, \n hospice care \n physicians) to prescribe Schedule II-V controlled substances via <span class=\"match\">telemedicine</span>, and (3) a \n <span class=\"match\">Telemedicine</span> Platform Registration, \n authorizing \n covered online <span class=\"match\">telemedicine</span> platforms, \n in"},{"title":"Expansion of Buprenorphine Treatment via Telemedicine Encounter","type":"Rule","abstract":"The Drug Enforcement Administration and the Department of Health and Human Services are amending their regulations to expand the circumstances under which practitioners registered by the Drug Enforcement Administration are authorized to prescribe schedule III-V controlled substances approved by the Food and Drug Administration for the treatment of opioid use disorder via a telemedicine encounter, including an audio-only telemedicine encounter. Under these new regulations, after a practitioner reviews the patient's prescription drug monitoring program data for the state in which the patient is located during the telemedicine encounter, the practitioner may prescribe an initial six-month supply of such medications (split amongst several prescriptions totaling six calendar months) through audio-only means. Additional prescriptions can be issued under other forms of telemedicine as authorized under the Controlled Substances Act, or after an in-person medical evaluation is conducted. This regulation also requires the pharmacist to verify the identity of the patient prior to filling a prescription. The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 generally requires an in- person medical evaluation prior to issuance of a controlled substance prescription. However, this regulation falls under one of the exceptions found within the Ryan Haight Act. Additionally, this regulation does not affect practitioner-patient relationships in cases where an in-person medical evaluation has previously occurred. The purpose of this regulation is to prevent lapses of care by continuing some of the telemedicine flexibilities that currently exist for those patients seeking treatment for opioid use disorder.","document_number":"2025-01049","html_url":"https://www.federalregister.gov/documents/2025/01/17/2025-01049/expansion-of-buprenorphine-treatment-via-telemedicine-encounter","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-01-17/pdf/2025-01049.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-01049.pdf?1736948756","publication_date":"2025-01-17","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"},{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"}],"excerpts":"one of the seven distinct categories of <span class=\"match\">telemedicine</span> envisioned under the statutory definition of the practice of <span class=\"match\">telemedicine</span>. In order to prevent lapses in care, these exceptions authorized the prescribing of controlled-substance medications via <span class=\"match\">telemedicine</span> encounters even when the prescribing practitioner had not conducted an in-person medical evaluation of the patient. These <span class=\"match\">telemedicine</span> flexibilities authorized practitioners to prescribe schedule II-V controlled substances via audio-video <span class=\"match\">telemedicine</span> encounters, including schedule III-V controlled"},{"title":"Continuity of Care via Telemedicine for Veterans Affairs Patients","type":"Rule","abstract":"This final rule authorizes Department of Veterans Affairs (VA) practitioners acting within the scope of their VA employment to prescribe controlled substances via telemedicine to a VA patient with whom they have not conducted an in-person medical evaluation. VA practitioners are permitted to prescribe controlled substances to VA patients if another VA practitioner has, at any time, previously conducted an in-person medical evaluation of the VA patient, subject to certain conditions.","document_number":"2025-01044","html_url":"https://www.federalregister.gov/documents/2025/01/17/2025-01044/continuity-of-care-via-telemedicine-for-veterans-affairs-patients","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-01-17/pdf/2025-01044.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-01044.pdf?1736948756","publication_date":"2025-01-17","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"},{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"}],"excerpts":"encounter. Moreover, each prescription issued via a <span class=\"match\">telemedicine</span> encounter would be required to bear a notation on its face indicating it was issued via a <span class=\"match\">telemedicine</span> encounter. These extra safeguards were intended to provide an additional layer of transparency for DEA audits and investigations. \n The General <span class=\"match\">Telemedicine</span> NPRM proposed certain provisions for VA practitioners prescribing controlled substances via <span class=\"match\">telemedicine</span>. Specifically, VA practitioners prescribing controlled substances during <span class=\"match\">telemedicine</span> encounters with VA patients utilizing the VA"},{"title":"Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications","type":"Rule","abstract":"The Drug Enforcement Administration (DEA) in concert with the Department of Health and Human Services (HHS) is issuing a third extension of telemedicine flexibilities for the prescribing of controlled medications, through December 31, 2025.","document_number":"2024-27018","html_url":"https://www.federalregister.gov/documents/2024/11/19/2024-27018/third-temporary-extension-of-covid-19-telemedicine-flexibilities-for-prescription-of-controlled","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-11-19/pdf/2024-27018.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-27018.pdf?1731705322","publication_date":"2024-11-19","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"},{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"}],"excerpts":"Register \n —“<span class=\"match\">Telemedicine</span> Prescribing of Controlled Substances When the Practitioner and the Patient Have Not Had a Prior In-Person Medical Evaluation” \n 3 \n \n (the General <span class=\"match\">Telemedicine</span> NPRM) and “Expansion of Induction of Buprenorphine via <span class=\"match\">Telemedicine</span> Encounter” \n 4 \n \n (the Buprenorphine NPRM)—which proposed to expand patient access to prescriptions for controlled medications via <span class=\"match\">telemedicine</span> encounters relative to the pre-COVID-19 PHE landscape. The purpose of the two proposed rules was to make permanent some of the <span class=\"match\">telemedicine</span> flexibilities"},{"title":"Practice of Telemedicine: Listening Sessions","type":"Notice","abstract":"The Drug Enforcement Administration (DEA) is conducting public listening sessions to receive additional input concerning the practice of telemedicine with regards to controlled substances and potential safeguards that could effectively prevent and detect diversion of controlled substances prescribed via telemedicine. Specifically, DEA is inviting all interested persons, including medical practitioners, patients, pharmacy professionals, industry members, law enforcement, and other third parties to express their views at the listening sessions concerning the advisability of permitting telemedicine prescribing of certain controlled substances without any in-person medical evaluation at all, the availability and types of data that would be useful in detecting diversion of controlled substances via telemedicine that are either already reported or could be reported, and specific additional safeguards that could be placed around the prescribing of schedule II controlled substances via telemedicine.","document_number":"2023-16889","html_url":"https://www.federalregister.gov/documents/2023/08/07/2023-16889/practice-of-telemedicine-listening-sessions","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2023-08-07/pdf/2023-16889.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2023-16889.pdf?1691153144","publication_date":"2023-08-07","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"notices of proposed rulemaking (NPRMs) in the \n Federal Register \n —\n <span class=\"match\">Telemedicine</span> Prescribing of Controlled Substances When the Practitioner and the Patient Have Not Had a Prior In-Person Medical Evaluation \n  \n 2 \n \n (the “General <span class=\"match\">Telemedicine</span> NPRM”) and \n Expansion of Induction of Buprenorphine via <span class=\"match\">Telemedicine</span> Encounter \n  \n 3 \n \n (the “Buprenorphine NPRM”).\n 4 \n \n These proposed rules sought to expand patient access to prescriptions for controlled substances via <span class=\"match\">telemedicine</span> encounters relative to the pre-COVID-19 PHE landscape, when consistent"},{"title":"Second Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications","type":"Rule","abstract":"On March 1, 2023 the Drug Enforcement Administration (DEA), in concert with the Department of Health and Human Services (HHS), promulgated two notices of proposed rulemakings (NPRMs) soliciting comments on proposals to allow for prescribing of controlled medications pursuant to the practice of telemedicine in instances where the prescribing practitioner has never conducted an in-person medical evaluation of the patient. On May 10, 2023, following initial review of the comments received, DEA, jointly with HHS, issued a temporary rule (First Temporary Rule) extending certain exceptions granted to existing DEA regulations in March 2020 as a result of the COVID-19 Public Health Emergency (COVID-19 PHE). These exceptions were granted in order to avoid lapses in care for patients. In particular, with respect to practitioner-patient relationships formed after the May 11, 2023, expiration of the COVID-19 PHE, the First Temporary Rule extended the temporary exceptions until November 11, 2023. In this second temporary rule, as DEA and HHS continue to consider revisions to the proposed rules set forth in the March 1, 2023 NPRMs and in light of Telemedicine Listening Sessions that DEA hosted on September 12 and 13, 2023, DEA and HHS are further extending such exceptions to existing DEA regulations for new practitioner-patient relationships through December 31, 2024.","document_number":"2023-22406","html_url":"https://www.federalregister.gov/documents/2023/10/10/2023-22406/second-temporary-extension-of-covid-19-telemedicine-flexibilities-for-prescription-of-controlled","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2023-10-10/pdf/2023-22406.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2023-22406.pdf?1696596394","publication_date":"2023-10-10","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"},{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"}],"excerpts":"Register \n —“<span class=\"match\">Telemedicine</span> Prescribing of Controlled Substances When the Practitioner and the Patient Have Not Had a Prior In-Person Medical Evaluation” \n 3 \n \n (the General <span class=\"match\">Telemedicine</span> Rule) and “Expansion of Induction of Buprenorphine via <span class=\"match\">Telemedicine</span> Encounter” \n 4 \n \n (the Buprenorphine Rule)—which proposed to expand patient access to prescriptions for controlled medications via <span class=\"match\">telemedicine</span> encounters relative to the pre-COVID-19 PHE landscape. The purpose of the two proposed rules was to make permanent some of the <span class=\"match\">telemedicine</span> flexibilities"},{"title":"Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications","type":"Rule","abstract":"On March 1, 2023 the Drug Enforcement Administration (DEA), in concert with the Department of Health and Human Services (HHS), promulgated two notices of proposed rulemakings (NPRMs) soliciting comments on proposals to allow for prescribing of controlled medications pursuant to the practice of telemedicine in instances where the prescribing practitioner has never conducted an in-person medical evaluation of the patient. Those NPRMs resulted in 38,369 public comments, which are being closely reviewed. DEA, in concert with HHS, is considering revisions to the proposed rules set forth in the NPRMs. In the meantime, and following initial review of the comments received, DEA, jointly with the Substance Abuse and Mental Health Services Administration (SAMHSA), is issuing this temporary rule to extend certain exceptions granted to existing DEA regulations in March 2020 as a result of the COVID-19 Public Health Emergency (COVID-19 PHE), in order to avoid lapses in care for patients. Ultimately, there will be a final set of regulations permitting the practice of telemedicine under circumstances that are consistent with public health, safety, and effective controls against diversion.","document_number":"2023-09936","html_url":"https://www.federalregister.gov/documents/2023/05/10/2023-09936/temporary-extension-of-covid-19-telemedicine-flexibilities-for-prescription-of-controlled","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2023-05-10/pdf/2023-09936.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2023-09936.pdf?1683636324","publication_date":"2023-05-10","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"},{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"}],"excerpts":"Register \n —“<span class=\"match\">Telemedicine</span> prescribing of controlled substances when the practitioner and the patient have not had a prior in-person medical evaluation” \n 3 \n \n (the General <span class=\"match\">Telemedicine</span> Rule) and “Expansion of induction of buprenorphine via <span class=\"match\">telemedicine</span> encounter” \n 4 \n \n (the Buprenorphine Rule)—which proposed to expand patient access to prescriptions for controlled medications via <span class=\"match\">telemedicine</span> encounters relative to the pre-COVID-19 PHE landscape. The purpose of the two proposed rules was to make permanent some of the <span class=\"match\">telemedicine</span> flexibilities"},{"title":"Expansion of Induction of Buprenorphine via Telemedicine Encounter","type":"Proposed Rule","abstract":"The Drug Enforcement Administration (DEA) is amending its regulations, in concert with the Department of Health and Human Services (HHS), to expand the circumstances under which individual practitioners are authorized to prescribe schedule III-V narcotic drugs or combinations of such drugs that have been approved for use in continuous medical treatment (also referred to as maintenance) or withdrawal management treatment (also referred to as detoxification)-- via a telemedicine encounter, including an audio-only telemedicine encounter.","document_number":"2023-04217","html_url":"https://www.federalregister.gov/documents/2023/03/01/2023-04217/expansion-of-induction-of-buprenorphine-via-telemedicine-encounter","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2023-03-01/pdf/2023-04217.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2023-04217.pdf?1677526230","publication_date":"2023-03-01","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"practitioner is “engaged in the practice of <span class=\"match\">telemedicine</span>” \n 7 \n \n within the meaning of the Ryan Haight Act (21 U.S.C. 802(54)). Consistent with the Ryan Haight Act's purpose of preventing diversion of controlled substances by means of the internet, the Act's definition of “the practice of <span class=\"match\">telemedicine</span>” does not encompass all forms of <span class=\"match\">telemedicine</span>. Rather, as set forth in 21 U.S.C. 802(54), the Ryan Haight Act's definition of the “practice of <span class=\"match\">telemedicine</span>” includes seven distinct categories of <span class=\"match\">telemedicine</span> that Congress determined were appropriate"},{"title":"Telemedicine Prescribing of Controlled Substances When the Practitioner and the Patient Have Not Had a Prior In-Person Medical Evaluation","type":"Proposed Rule","abstract":"Under the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 and Drug Enforcement Administration's (DEA) implementing regulations, after a patient and a practitioner have had an in-person medical evaluation, that practitioner may use telehealth to prescribe that patient any prescription for a controlled medication that the practitioner deems medically necessary. The Ryan Haight Act and DEA's implementing regulations do not apply to other forms of telemedicine, telehealth, or telepsychiatry that are not otherwise addressed in the Controlled Substances Act. This proposed rule applies only in limited circumstances when the prescribing practitioner wishes to prescribe controlled medications via the practice of telemedicine and has not otherwise conducted an in-person medical evaluation prior to the issuance of the prescription.","document_number":"2023-04248","html_url":"https://www.federalregister.gov/documents/2023/03/01/2023-04248/telemedicine-prescribing-of-controlled-substances-when-the-practitioner-and-the-patient-have-not-had","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2023-03-01/pdf/2023-04248.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2023-04248.pdf?1677526230","publication_date":"2023-03-01","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"following terms: practice of <span class=\"match\">telemedicine</span>; qualifying <span class=\"match\">telemedicine</span> referral; <span class=\"match\">telemedicine</span> encounter; <span class=\"match\">telemedicine</span> prescription; and <span class=\"match\">telemedicine</span> relationship established during the COVID-19 public health emergency. In addition, DEA proposes to amend its regulations to clarify one aspect of the definition of the practice of <span class=\"match\">telemedicine</span>, and to remove an expired paragraph that provided a temporary definition of the practice of <span class=\"match\">telemedicine</span>. \n DEA proposes to amend its regulatory definition of the term “practice of <span class=\"match\">telemedicine</span>” to better explain, but"},{"title":"Neeraj B. Shah, M.D.; Decision and Order","type":"Notice","abstract":null,"document_number":"2024-24189","html_url":"https://www.federalregister.gov/documents/2024/10/21/2024-24189/neeraj-b-shah-md-decision-and-order","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-10-21/pdf/2024-24189.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-24189.pdf?1729255522","publication_date":"2024-10-21","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"of professional practice and without a legitimate medical purpose. RD, at 24-27. \n Respondent's Hard Token, Credentials, and Electronic Prescribing \n \n In July 2019, Respondent \n 3 \n \n received an unsolicited fax offering employment as a prescribing practitioner with a <span class=\"match\">telemedicine</span> platform called Church Ekklasia Sozo (CES).\n 4 \n \n RD, at 11-12; Tr. 184-86, 327; Respondent's Exhibit (RX) 1. The company was based out of North Carolina and Respondent lived and worked in Texas. RD, at 4, 10, 12; ALJX 8, at 2, Stips. 1-3. Respondent joined CES in September"},{"title":"David Bockoff, M.D.; Decision and Order","type":"Notice","abstract":null,"document_number":"2025-02421","html_url":"https://www.federalregister.gov/documents/2025/02/10/2025-02421/david-bockoff-md-decision-and-order","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-02-10/pdf/2025-02421.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-02421.pdf?1738942595","publication_date":"2025-02-10","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"previously examined the patient in person. \n Id. \n If so, then the “[p]ractitioner may conduct any needed follow-up evaluation by any method in person, <span class=\"match\">telemedicine</span>, telephone, email, etc.” \n Id. \n If not, then a Practitioner who is prescribing “buprenorphine for maintenance or detoxification treatment of an opioid use disorder . . . [e]valuate[s the] patient . . . in person, or via <span class=\"match\">telemedicine</span> using a real-time, two-way, audio-visual communications device.” \n Id. \n If the practitioner has not previously examined the patient in person and is not"},{"title":"Muhamad Aly Rifai, M.D.; Decision and Order","type":"Notice","abstract":null,"document_number":"2026-21258","html_url":"https://www.federalregister.gov/documents/2026/10/19/2026-21258/muhamad-aly-rifai-md-decision-and-order","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-19/pdf/2026-21258.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-21258.pdf?1792154712","publication_date":"2026-10-19","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"Patient Health Questionnaire (PHQ-9); GAD-7 Anxiety; and Adult ADHD Self-Report Scale Symptom Checklist. RFAAX 32, at 1-38. Additionally, Respondent submitted the following documentation: Psychiatric Progress Notes indicating an in-person appointment on May 17, 2021; a video <span class=\"match\">telemedicine</span> follow-up on June 11, 2021; and a telehealth appointment on August 9, 2021; Urine Drug Screen—12 Panel Integrated Test Cup with results dated August 9, 2021; a letter dated August 9, 2021, to UC informing her that Respondent can no longer provide UC with psychiatric services"},{"title":"Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2025","type":"Notice","abstract":"The Drug Enforcement Administration (DEA) proposes to establish the 2025 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act (CSA) and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.","document_number":"2024-21962","html_url":"https://www.federalregister.gov/documents/2024/09/25/2024-21962/proposed-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances-and-assessment-of","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-09-25/pdf/2024-21962.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-21962.pdf?1726863312","publication_date":"2024-09-25","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"shortage notifications it received since 2022 from patients for specific ADHD medications containing amphetamine, lisdexamfetamine, and methylphenidate. FDA's stated reasons for these specific shortages include increased prescribing potentially related to the growth in <span class=\"match\">telemedicine</span> during and after the COVID-19 PHE, supply chain issues, manufacturing and quality issues, lack of active ingredients, and business decisions of manufacturers. DEA considered FDA's concerns when determining the APQ for these substances. Additionally, DEA considered manufacturer"},{"title":"Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment","type":"Rule","abstract":"The \"Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018 (the SUPPORT Act),\" which became law on October 24, 2018, amended the Controlled Substances Act to expand the conditions a practitioner must meet to provide medication-assisted treatment for opioid use disorder and expand the options available for a physician to be considered a qualifying physician. The SUPPORT Act also allowed a pharmacy to deliver prescribed controlled substances to a practitioner's registered location for the purpose of maintenance or detoxification treatment to be administered under certain conditions by a practitioner. The Drug Enforcement Administration promulgated an interim final rule with request for comments in November 2020 to amend its regulations to make them consistent with the SUPPORT Act and implement its requirements. On December 29, 2022, the Restoring Hope for Mental Health and Well-Being Act of 2022 removed many of the statutory provisions of the SUPPORT Act. This final rule adopts the provisions of the interim final rule that are still applicable as final, with minor changes. In addition, this final rule implements the related provisions of the Restoring Hope for Mental Health and Well-Being Act of 2022.","document_number":"2026-11526","html_url":"https://www.federalregister.gov/documents/2026/06/09/2026-11526/implementation-of-the-substance-use-disorder-prevention-that-promotes-opioid-recovery-and-treatment","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-06-09/pdf/2026-11526.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-11526.pdf?1780922715","publication_date":"2026-06-09","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"disruptions in care when a DATA-waived practitioner is unavailable to administer the substance. The commenters maintained that this clarification will have a positive effect on patients in rural areas and in residential care facilities, and those receiving regular treatment via <span class=\"match\">telemedicine</span>, during natural disasters and during pandemics. \n \n DEA Response 3: \n As noted by three commenters, the CSA's definition of “practitioner” includes a “pharmacy . . . or other person licensed, registered, or otherwise permitted, by the United States or the jurisdiction"},{"title":"Rachel Pittala, APRN; Decision and Order","type":"Notice","abstract":null,"document_number":"2023-19819","html_url":"https://www.federalregister.gov/documents/2023/09/14/2023-19819/rachel-pittala-aprn-decision-and-order","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2023-09-14/pdf/2023-19819.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2023-19819.pdf?1694609123","publication_date":"2023-09-14","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"confident and comfortable” trusting S.H.'s opinion and S.H. had “felt that it was a good practice” despite a lack of published studies regarding the use of Adderall for managing drug abuse. RD, at 9; Tr. 244-245, 249.\n \n \n \n \n 7 \n  Respondent exclusively provided care via <span class=\"match\">telemedicine</span> and never went to Sawgrass Health. RD, at 8; Tr. 232, 351. Following an in-person visit with a new patient, S.H. would contact Respondent to assign her the patient, give Respondent background on the patient, state a diagnosis, and make recommendations about treatment."},{"title":"Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2023","type":"Notice","abstract":"This final order establishes the initial 2023 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.","document_number":"2022-26351","html_url":"https://www.federalregister.gov/documents/2022/12/02/2022-26351/established-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances-and-assessment","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2022-12-02/pdf/2022-26351.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2022-26351.pdf?1669824918","publication_date":"2022-12-02","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"DEA Administrator, designated that the <span class=\"match\">telemedicine</span> allowance under 21 U.S.C. 802(54)(D) applies to all schedule II-V controlled substances in all areas of the United States. This allowance was part of the Ryan Haight Act's amendments to the CSA. Accordingly, as of March 16, 2020, and continuing for as long as the Secretary's designation of a public health emergency remains in effect, the <span class=\"match\">telemedicine</span> allowance under 21 U.S.C. 802(54)(D) applies. However, the majority of the issues pertaining to <span class=\"match\">telemedicine</span> are outside the scope of this rule, which"},{"title":"Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2024","type":"Notice","abstract":"The Drug Enforcement Administration (DEA) proposes to establish the 2024 aggregate production quotas (APQ) for controlled substances in schedules I and II of the Controlled Substances Act (CSA) and the assessment of annual needs (AAN) for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. For the 2024 quota year, DEA intends to allocate procurement quotas to DEA-registered manufacturers of schedule II controlled substances on a quarterly basis. In order to address domestic drug shortages of controlled substances, procurement quota allocations will be divided between quantities authorized for domestic sales and quantities authorized for export sales.","document_number":"2023-24282","html_url":"https://www.federalregister.gov/documents/2023/11/02/2023-24282/proposed-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances-and-assessment-of","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2023-11-02/pdf/2023-24282.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2023-24282.pdf?1698842901","publication_date":"2023-11-02","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"also raised concerns over drug shortage notifications it received from patients for specific ADHD medications containing methylphenidate and amphetamine. FDA's stated reasons for these specific shortages include increased prescribing potentially related to the growth in <span class=\"match\">telemedicine</span>, supply chain issues, manufacturing and quality issues, and business decisions of manufacturers. DEA considered FDA's concerns when determining the APQ for these substances. DEA believes that manufacturers will be able to meet the increase in domestic medical need with"}]}